Metabolic syndrome (MetS), including obesity, hyperglycemia, hyperlipidemia, hyperinsulinemia, are associated with disturbed energy homeostasis, limited whole-body insulin sensitivity, and an increased risk of cardiovascular and chronic kidney disease (CKD). The prospective and cross-sectional studies have shown a close association between the MetS and CKD. Chronic inflammation and vascular dysfunction are two key MetS-related etiological factors for renal injury. CKD is characterized by mitochondrial dysfunction, oxidative stress, and aberrant autophagy at the cellular level, which is also typical of metabolic disorders. However, the relationship and mechanism between metabolic disease and chronic kidney dysfunction still call for deeper understanding. This Research Topic aims to gather both Reviews and Original Research articles focused on discovering the truth behind the phenomenon that glucose and lipid metabolic disorders and obesity have important public health implications in terms of individuals with CKD. The studies covering new insights to determine the link between MetS-related immunity response and renal dysfunction will also be considered.

This volume provides an overview of the biochemical basis of metabolic diseases and molecular basis of chemical pathologies. Metabolic disorders occur when metabolic processes in the body are disrupted. They contribute a significant burden to human health globally. They can be congenital or acquired, for example, diabetes mellitus, obesity, metabolic syndrome, osteoporosis, osteopenia, mild-moderate hypovitaminosis D, erectile dysfunction, dyslipidemia, and thyroiditis. Metabolic disorders have gained significant importance due to the exponential increase in obesity worldwide. Early diagnosis of metabolic disorders is important in order to employ lifestyle and risk factor modification. Features: An overview of the biochemical basis of metabolic diseases and molecular basis of chemical pathologies Describes recent trends in diagnosis of metabolic disorders Discusses management and treatment of metabolic diseases Allows quick identification and retrieval of material by researchers learning the efficacy, associated dosage and toxicity of each of the classes of compounds Suitable globally for graduate and postgraduate students studying metabolic diseases

This book is open access under a CC BY 4.0 license. ​This handbook synthesizes and analyzes the growing knowledge base on life course health development (LCHD) from the prenatal period through emerging adulthood, with implications for clinical practice and public health. It presents LCHD as an innovative field with a sound theoretical framework for understanding wellness and disease from a lifespan perspective, replacing previous medical, biopsychosocial, and early genomic models of health. Interdisciplinary chapters discuss major health concerns (diabetes, obesity), important less-studied conditions (hearing, kidney health), and large-scale issues (nutrition, adversity) from a lifespan viewpoint. In addition, chapters address methodological approaches and challenges by analyzing existing measures, studies, and surveys. The book concludes with the editors’ research agenda that proposes priorities for future LCHD research and its application to health care practice and health policy. Topics featured in the Handbook include: The prenatal period and its effect on child obesity and metabolic outcomes. Pregnancy complications and their effect on women’s cardiovascular health. A multi-level approach for obesity prevention in children. Application of the LCHD framework to autism spectrum disorder. Socioeconomic disadvantage and its influence on health development across the lifespan. The importance of nutrition to optimal health development across the lifespan. The Handbook of Life Course Health Development is a must-have resource for researchers, clinicians/professionals, and graduate students in developmental psychology/science; maternal and child health; social work; health economics; educational policy and politics; and medical law as well as many interrelated subdisciplines in psychology, medicine, public health, mental health, education, social welfare, economics, sociology, and law.

Previous studies reported an association between metabolic syndrome and incident chronic kidney disease (CKD). The objective of this analysis was to study the associations between metabolic syndrome and its components with end stage renal disease (ESRD) and death among those CKD. Patients with stage 3 and stage 4 CKD (n=25,868) who had data relating to metabolic syndrome were included. Cox proportional hazards models and competing risk analyses were used to study the associations between metabolic syndrome, its components and all-cause mortality and ESRD. Sixty percent of the study population (n=15,605) had metabolic syndrome. In the multivariate adjusted analysis, presence of metabolic syndrome was associated with 33% increased risk for ESRD, but not for death. Among the individual components of metabolic syndrome, impaired glucose metabolism, elevated triglycerides and hypertension were associated with increased risk for ESRD while low HDL cholesterol and impaired glucose metabolism were associated with higher risk of death.

This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.

That precursors of adult coronary artery disease, hypertension, and type II diabetes begin in childhood have been clearly established by the Bogalusa Heart Study. This unique research program has been able to follow a biracial (black/white) population over 35 years from childhood through mid-adulthood to provide perspectives on the natural history of adult heart diseases. Not only do these observations describe trajectories of cardio-metabolic risk variables leading to these diseases but provide a rationale for the need to begin prevention beginning in childhood. The trajectories of the burden of cardio-metabolic risk variables in the context of their fetal origin and chromosome telomere dynamics provide some insight into the metabolic imprinting in utero and aging process. The observed racial contrasts on cardio-metabolic risk variables implicate various biologic pathways interacting with environment contributing to the high morbidity and mortality from related diseases in our population. To address the seriousness of the onset of cardiovascular disease in youth, approaches to primordial prevention are described focussing on childhood health education as an important aspect of Preventive Cardiology.